Company profile
GeneDx Holdings Corp.
NASDAQ: WGS · Healthcare · Medical - Healthcare Information Services
#224 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
64CFH 65DQ 64GM 57SS 68
v0.1 · 65/100 weight · provisional
↑ filing timeliness, market scale · ↓ Piotroski F, listing tenure
Methodology →Revenue TTM
$442.7M
Rev growth YoY (TTM)
+34.1%
Net income (FY)
-$21.0M
Employees
1,300
as of 2026-08-09
Market cap
$2.3B
as of 2026-08-09
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$427.5M$427.5M2025
Net income-$21.0M-$21.0M2025
Operating income-$13.1M-$13.1M2025
Total assets$523.7M$523.7M2025
Liabilities$215.5M$215.5M2025
Equity$308.2M$308.2M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY21
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Diagnostic Test49%
Diagnostic Test, Third Party Insurance41%
Diagnostic Test, Institutional Customers8%
Product and Service, Other1%
Diagnostic Test, Self Pay0%
By geography
Not disclosed.
The read
What is GeneDx Holdings Corp.’s revenue?
GeneDx Holdings Corp. booked $427.5M in FY2025 revenue, growing 40% year over year — faster than most Healthcare companies we track, at a -4.9% net margin.
Peers · Healthcare
Tarsus Pharmaceuticals, Inc.62CArtivion, Inc.80B+Atlantic International Corp.39DCertara, Inc.68BMiMedx Group, Inc.85AInnoviva, Inc.83B+Neighbors
Fairfield →Key facts
CEOKatherine A. Stueland
SectorHealthcare
IndustryMedical - Healthcare Information Services
HeadquartersStamford, CT
ExchangeNASDAQ: WGS
Employees1,300
IPO date2020-11-04
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.